Hims & Hers Health Inc

Hims & Hers Health Inc(HIMS)股票分析

$28.150

+0.082 (+0.29%)收盘时

Loading chart…
最高
29.000
开盘
28.490
成交量加权均价
28.23
成交量
7.45M
市值
4.30B
最低
27.530
成交额
210.36M
企业价值/息税折旧摊销前利润(TTM)
-18.44

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.

AI 分析 of Hims & Hers Health Inc (HIMS)

持有

Hims & Hers Health Inc is currently a hold. The stock is trading at $28.07, which is below several analyst price targets, including $32 from JPMorgan and $35 from Barclays. However, the company is facing significant challenges, including a net loss of $142 million and a declining gross margin of 63.83%. The recent insider sale of 6,236 shares by the Chief Legal Officer, despite retaining a significant stake, raises concerns about management's confidence amid a 45% decline in stock price over the past year. The main risk is the ongoing class action lawsuit that could impact the company's reputation and financial standing.

估值指标

Hims & Hers Health Inc(HIMS)当前预期市盈率为 73.53,5 年平均预期市盈率为 18.16。

预期市盈率

合理
5 年均值 P/E
18.16
当前P/E
73.53
高估
75.92
低估
-39.61

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
13.55
当前EV/EBITDA
-18.44
高估
46.30
低估
-19.19

预期市销率

合理
5 年均值 P/S
2.49
当前P/S
1.71
高估
3.55
低估
1.43

Alphio AI 对 HIMS 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%HIMS

$133.17

情景价格

基

基准

基准 · 50%HIMS

$111.56

情景价格

悲

悲观

悲观 · 25%HIMS

$85.01

情景价格

持有 HIMS 的大户

B

BIT Capital GmbH

+ 持有HIMS

-5.27%

3个月收益率

C

Casdin Capital, LLC

+ 持有HIMS

-5.77%

3个月收益率

H

HANSAINVEST Hanseatische Investment-GmbH

+ 持有HIMS

-15.95%

3个月收益率

W

Wolverine Asset Management, LLC

+ 持有HIMS

-17.32%

3个月收益率

事件时间线

2026-10-12 (ET)

15:30:00

Hims & Hers Officially Launches Hers in Australia

2026-10-09 (ET)

14:30:00

Hims and Hers Health Shares Rise 7.5%

2026-10-08 (ET)

16:30:00

Major Averages Decline Amid Rising Oil Prices

12:30:00

Major Averages Decline as Oil Prices Surge

2026-10-07 (ET)

16:30:00

Hims & Hers Health Appoints Jon Franklin as Chief Accounting Officer

资讯

HIMS 常见问题 —— 由 Alphio AI 解答

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

Hims & Hers Health Inc is currently a hold. The stock is trading at $28.07, which is below several analyst price targets, including $32 from JPMorgan and $35 from Barclays. However, the company is facing significant challenges, including a net loss of $142 million and a declining gross margin of 63.83%. The recent insider sale of 6,236 shares by the Chief Legal Officer, despite retaining a significant stake, raises concerns about management's confidence amid a 45% decline in stock price over the past year. The main risk is the ongoing class action lawsuit that could impact the company's reputation and financial standing.

HIMS stock ended a three-day decline on peptide hopes: the Trump administration is reviewing a plan that could open a $2.2B market. $HIMS

展开
dawn_badger2026/10/9

$HIMS The price is wasting time ... but it's running out of room. Imminent resolution. Weekly chart

展开
注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易